RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors understand how patients respond to treatment. PURPOSE: This laboratory study is looking at gene expression in patients with advanced or metastatic colorectal cancer receiving bevacizumab.
OBJECTIVES: * Determine whether the balance of splice form expression alters susceptibility of tumors in vivo to respond to anti-VEGF therapy. OUTLINE: Tumor tissue samples collected on clinical trial E-3200 are analyzed for laboratory endpoints.
Study Type
OBSERVATIONAL
Enrollment
200
Mean scores for VEGFb and pan-VEGF gene expression by IHC
Time frame: 1 month
Gene expression as measured by tissue microarrays
Time frame: 1 month
Splice form expression as measured by reverse transcriptase-PCR
Time frame: 1 month
VEGF165b protein expression as measured by ELISA
Time frame: 1 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.